FDA Brief

Warning letters Biologics

FDA warning letter to

Utah Cord Bank LLC

High riskIssued May 11, 2021Posted Jun 1, 2021Office Biological Products Operations – Division 2

FDA cited Utah Cord Bank for unvalidated cord blood processing, missing environmental monitoring, procedures, and records after a February 2021 inspection.

What happened

FDA inspected Utah Cord Bank's Sandy, Utah facility from February 1-11, 2021 and documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT/Ps). FDA found the company had not validated its processing or microbiological testing, did not monitor environmental conditions where cord blood was exposed during vial filling, and lacked required procedures and records. FDA also asked the company to clarify whether its products are only for a patient's own use or also for use in a first- or second-degree blood relative.

What FDA found

  1. The company did not validate the manufacturing process or its microbiological testing, and did not document and approve the validation with dates and signatures.

    21 CFR 1271.230(a)
  2. The company did not monitor environmental conditions for microorganisms where cord blood was drained from the collection bag into vials, a step that could cause contamination.

    21 CFR 1271.195(c)
  3. The company lacked written and maintained procedures for facility cleaning and maintenance, environmental control, equipment, supplies and reagents, processing, labeling, storage, and receipt, shipment, and distribution.

    21 CFR 1271.180(a)
  4. The company did not keep complete records made at the time of work for cleaning, environmental monitoring, equipment, supplies and reagents, storage temperatures, recovery, processing including sterility testing, and complaints.

    21 CFR 1271.270(a)

What FDA wants

FDA asks Utah Cord Bank to respond in writing within 15 working days with specific corrective steps, supporting documentation, and a plan to prevent recurrence, and to clarify all intended uses of its products. If corrections cannot be completed in that time, FDA asks for the reason and a timeline for the remaining work.

Who should pay attention

  • cord blood banks and other HCT/P manufacturers
  • clinics and transplant programs that use banked cord blood
  • suppliers and consultants serving HCT/P establishments

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Beaute Bounty

    FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.

    High risk
  2. Blue Horizon International, LLC

    FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.

    High risk
  3. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  4. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk